Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

DIRECT/InspIRE Australia : Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy (DIRECT/InspIRE Australia)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Surgical<br/>TrialTypeSurgical
Trial

UnknownPhase Unknown

Pancreas<br/>CancersCancer LocationPancreas
Cancers

Surgical | Stomach and upper gastrointestinal tractPancreas

Trial Overview Read MoreRead more

This study is evaluating the effectiveness of a procedure called irreversible electroporation, which uses electrical pulses to destroy cancer cells, in people with stage III pancreatic cancer who have received 3 months of chemotherapy.
 

This trial is treating patients with unresectable, stage III pancreatic cancer.

This is a surgical trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy (DIRECT/InspIRE Australia)

Commercial Sponsor

AngioDynamics

Other Non-Commercial Sponsor

Walter and Eliza Hall Institute

Summary

This is an open-label, prospective, multi-centre registry-based study evaluating the use of Irreversible Electroporation (IRE) with the NanoKnife system in unresectable stage 3 pancreatic cancer. Irreversible electroporation (IRE) is a technique using non-thermal energy to create permanent nanopores in the cell membrane in order to disrupt cellular homeostasis. After delivering a sufficient number of high voltage pulses, the cells within the electrical field will be irreversibly damaged. Eligible participants must have received 3 months of FOLFIRINOX or gemcitabine-based chemotherapy prior to enrolment. All participants will undergo IRE with the NanoKnife System, and the IRE procedure should be undertaken 1-3 weeks from the completion of 3 months of chemotherapy. Only a surgeon qualified in the use of the NanoKnife System will perform the procedure, and the procedure takes around 2-3 hours.

Recruiting Hospitals Read MoreRead more

Epworth Freemasons, Jreissati Family Pancreatic Centre
East Melbourne
Alishiya Murali
EHJreissatiCentre@epworth.org.au
03 9426 8880

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next